Literature DB >> 31676976

Cardiopulmonary Exercise Testing Allows Discrimination Between Idiopathic Non-specific Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis in Mild to Moderate Stages of the Disease.

Lars Hagmeyer1,2, Simon Herkenrath3,4, Norbert Anduleit3, Marcel Treml3, Winfried Randerath3,4.   

Abstract

It is unclear whether there are cardiopulmonary exercise testing (CPET) parameters which may indicate poor prognosis in the early course of fibrosing interstitial lung disease. 27 untreated consecutive subjects (13 idiopathic non-specific interstitial pneumonia (iNSIP), 14 idiopathic pulmonary fibrosis (IPF); 19 male; age 69 ± 10 years) were enrolled in this observational pilot study. Subjects underwent routine pulmonary function testing and CPET. Statistically, the t test and the Mann-Whitney-U test were applied in the presence of normal and non-normal distribution (according to Shapiro-Wilk), respectively. Analyzing the whole cohort, only mild functional impairments were determined. Comparison of iNSIP and IPF groups detected significant differences for the CPET parameters V'O2Peak[%pred] (p = 0.011), V'O2/kgPeak (p = 0.033), Watt[%pred] (p = 0.048), V'E/V'CO2 (Rest: p = 0.016; AT: p = 0.011; Peak: p = 0.019; Slope: p = 0.040), V'E/V'O2 (Rest: p = 0.033 AT: p = 0.014; Peak: p = 0.035). CPET parameters may indicate IPF-specific impairments even in mild disease. It may be hypothesized that these parameters are early biomarkers of poor prognosis.

Entities:  

Keywords:  Interstitial lung disease; Lung fibrosis; Prognosis; Pulmonary function test

Mesh:

Substances:

Year:  2019        PMID: 31676976     DOI: 10.1007/s00408-019-00282-9

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  20 in total

1.  Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis.

Authors:  K Miki; R Maekura; T Hiraga; Y Okuda; T Okamoto; A Hirotani; T Ogura
Journal:  Respir Med       Date:  2003-05       Impact factor: 3.415

2.  [Prognostic value of clinical exercise testing in idiopathic pulmonary fibrosis].

Authors:  B Wallaert; A Guetta; L Wemeau-Stervinou; G Tercé; M Valette; R Nevière; B Aguilaniu
Journal:  Rev Mal Respir       Date:  2011-02-22       Impact factor: 0.622

3.  Predicting survival across chronic interstitial lung disease: the ILD-GAP model.

Authors:  Christopher J Ryerson; Eric Vittinghoff; Brett Ley; Joyce S Lee; Joshua J Mooney; Kirk D Jones; Brett M Elicker; Paul J Wolters; Laura L Koth; Talmadge E King; Harold R Collard
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

4.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

5.  The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Lyrica Xiaohong Liu; Caroline Motika; Ella A Kazerooni; Barry H Gross; William D Travis; Thomas V Colby; Susan Murray; Galen B Toews; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2008-12-12       Impact factor: 21.405

6.  Physiological Profile and Limitations in Exercise in Idiopathic Pulmonary Fibrosis.

Authors:  Baruch Vainshelboim; Jose Oliveira; Benjamin Daniel Fox; Yochai Adir; Jacob Eliezer Ollech; Mordechai Reuven Kramer
Journal:  J Cardiopulm Rehabil Prev       Date:  2016 Jul-Aug       Impact factor: 2.081

7.  Common Mechanisms of Dyspnea in Chronic Interstitial and Obstructive Lung Disorders.

Authors:  Azmy Faisal; Bader J Alghamdi; Casey E Ciavaglia; Amany F Elbehairy; Katherine A Webb; Josuel Ora; J Alberto Neder; Denis E O'Donnell
Journal:  Am J Respir Crit Care Med       Date:  2016-02-01       Impact factor: 21.405

8.  Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis.

Authors:  A G Agustí; J Roca; J Gea; P D Wagner; A Xaubet; R Rodriguez-Roisin
Journal:  Am Rev Respir Dis       Date:  1991-02

Review 9.  IPF clinical trial design and endpoints.

Authors:  Steven D Nathan; Keith C Meyer
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

10.  The Role of Cardiopulmonary Exercise Test in IPF Prognosis.

Authors:  Christina Triantafillidou; Effrosyni Manali; Panagiotis Lyberopoulos; Likourgos Kolilekas; Konstantinos Kagouridis; Sotirios Gyftopoulos; Konstantinos Vougas; Anastasia Kotanidou; Manos Alchanatis; Anna Karakatsani; Spyros A Papiris
Journal:  Pulm Med       Date:  2013-10-31
View more
  3 in total

1.  Discriminating Between Non-Specific Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis at Early Stages: When CPET is Enough?

Authors:  Afroditi K Boutou
Journal:  Lung       Date:  2020-01-24       Impact factor: 2.584

2.  Feasibility of cardiopulmonary exercise testing in interstitial lung disease: the PETFIB study.

Authors:  Owen Tomlinson; Anna Duckworth; Laura Markham; Rebecca Wollerton; Bridget Knight; Alexander Spiers; Michael Gibbons; Craig Williams; Chris Scotton
Journal:  BMJ Open Respir Res       Date:  2021-04

3.  Value of Cardiopulmonary Exercise Testing in Prognostic Assessment of Patients with Interstitial Lung Diseases.

Authors:  Beate Stubbe; Till Ittermann; Anita Grieger; Charlotte Walther; Sven Gläser; Ralf Ewert
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.